Clinical trial
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for…
NCT00364013 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00364013 |
|---|---|
| Title | PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy |
| Official title | A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic Colorectal Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Panitumumab, FOLFOX regimen |
| Enrollment | 1,183 |
| Start date | Aug 1, 2006 |
| Primary completion | Aug 1, 2009 |
| Completion | Mar 22, 2013 |
| First posted | Aug 15, 2006 |
| Last update posted | Nov 7, 2022 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: